Clinical Trial Update: The Efficacy and Safety of HLX208 in Adult Langerhans Cell Histiocytosis (LCH) and Erdheim-Chester Disease (ECD) With BRAF V600E Mutation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating HLX208 for adult Langerhans Cell Histiocytosis and Erdheim-Chester Disease with BRAF V600E mutation; current status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erdheim-chester Disease
• Langerhans Cell Histiocytosis

Drugs mentioned

• HLX208

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Langerhans Cell Histiocytosis, Erdheim-Chester Disease | Phase 2 | Status: UNKNOWN